|
Soler-Espejo E, Zazo-Luengo BA, Rivera-Caravaca JM, Lopez-Gavez R, Esteve-Pastor MA, Lip GYH, Marin F, Roldan V. Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation. J Nutr Health Aging. 2025 Jan;29(1):100430. doi: 10.1016/j.jnha.2024.100430. Epub 2024 Nov 29. PubMed PMID: 39615399.
AÑO: 2025; IF: 4.0
|
|
Papakonstantinou P.E., Rivera-Caravaca J.M., Chiarito M., Ehrlinder H., Iliakis P., Gąsecka A., Romiti G.F., Parker W.A.E., Lip G.Y.H. Atrial fibrillation versus atrial myopathy in thrombogenesis: Two sides of the same coin?. Trends in Cardiovascular Medicine. 2025. 10.1016/j.tcm.2025.01.002
AÑO: 2025; IF: 9.0
|
|
Soler-Espejo E, Chen Y, Rivera-Caravaca JM, Ramos-Bratos MP, Lopez-Galvez R, Marin F, Roldan V, Lip GYH. Remnant-to-LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study. Cardiovasc Diabetol. 2025 Jul 10;24(1):275. doi: 10.1186/s12933-025-02831-4. PubMed PMID: 40640836; PubMed Central PMCID: PMC12243276.
AÑO: 2025; IF: 10.6
|
|
Soler-Espejo E, Ramos-Bratos MP, Chen Y, Gonzalez-Lozano E, Rivera-Caravaca JM, Marin F, Roldan V, Lip GYH. Phenotype-guided risk stratification in anticoagulated atrial fibrillation patients: Cluster analysis of the Murcia AF Project III (MAFP-III). Heart Rhythm. 2025 Sep 11:S1547-5271(25)02847-4. doi: 10.1016/j.hrthm.2025.09.003. Online ahead of print. PubMed PMID: 40945558.
AÑO: 2025; IF: 5.7
|
|
Frost F., Rivera-Caravaca J.M., Lip G.Y.H. The use of oral anticoagulation at the time of acute COVID-19 infection and subsequent development of long-COVID/post-acute sequelae of SARS-CoV-2 infection. Journal of Thrombosis and Thrombolysis. 2025. 10.1007/s11239-025-03096-0
AÑO: 2025; IF: 2.2
|